12/24
12:48 pm
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $7.00 price target on the stock.
Low
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $7.00 price target on the stock.
12/23
07:37 am
ganx
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease [Yahoo! Finance]
Low
Report
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease [Yahoo! Finance]
12/23
07:30 am
ganx
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
Low
Report
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
12/11
08:40 am
ganx
Gain Therapeutics To Present At Biotech Showcase 2025 [Yahoo! Finance]
Low
Report
Gain Therapeutics To Present At Biotech Showcase 2025 [Yahoo! Finance]
12/11
08:30 am
ganx
Gain Therapeutics To Present At Biotech Showcase 2025
Low
Report
Gain Therapeutics To Present At Biotech Showcase 2025
12/7
07:33 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/6
08:06 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $7.00 price target on the stock.
Low
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $7.00 price target on the stock.
11/25
08:04 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
11/15
07:35 am
ganx
Gain Therapeutics GAAP EPS of -$0.17 [Seeking Alpha]
Low
Report
Gain Therapeutics GAAP EPS of -$0.17 [Seeking Alpha]
11/14
04:17 pm
ganx
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update [Yahoo! Finance]
11/14
04:05 pm
ganx
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Medium
Report
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
10/23
08:00 am
ganx
Gain Therapeutics Presents Data at 36?? EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
Medium
Report
Gain Therapeutics Presents Data at 36?? EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
10/15
07:00 am
ganx
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Low
Report
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/9
08:33 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
10/9
08:30 am
ganx
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
Medium
Report
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
10/7
07:00 am
ganx
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
High
Report
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
10/3
07:00 am
ganx
Gain Therapeutics to Participate at Upcoming Investor Conferences
Medium
Report
Gain Therapeutics to Participate at Upcoming Investor Conferences
10/1
08:01 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
9/30
07:00 am
ganx
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
High
Report
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers